SABCS 2022 | Ki-67 index after neoadjuvant ET as a prognostic biomarker for HR+/HER2- early breast cancer

Diogo Martins-Branco, MD, MSc, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, shares a systematic review and meta-analysis of Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with HR-positive, HER2-negative early breast cancer. Ki-67 index is a prognostic biomarker in early breast cancer, often used in clinical trials as an endpoint for evaluating response to neoadjuvant endocrine therapy. A systematic literature search of PubMed, Embase, CENTRAL, and conference proceedings (ASCO and ESMO annual meetings, ESMO Breast, and SABCS) was conducted to identify clinical trials or observational studies reporting Ki-67 index after neoadjuvant endocrine therapy in patients with HR+/HER2- early breast cancer treated with neoadjuvant endocrine therapy. In this meta-analysis, a strong association between Ki-67 level after neoadjuvant endocrine therapy and survival endpoints, including overall-survival (OS) and recurrence-free survival (RFS) was demonstrated, reinforcing Ki-67 index after neoadjuvant endocrine therapy as a valuable biomarker of response or resistance to endocrine therapy in this patient populatuion. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.